Barclays
PRLD icon

Barclays’s Prelude Therapeutics PRLD Stock Holding History

Barclays’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4K Sell
8,600
-2
-0% -$5 ﹤0.01% 4488
2025
Q4 		$24.9K Sell
8,602
-110
-1% -$186 ﹤0.01% 4845
2025
Q3 		$12.5K Buy
8,712
+110
+1% +$110 ﹤0.01% 5002
2025
Q2 		$6.96K Sell
8,602
-14,543
-63% -$12.6K ﹤0.01% 4942
2025
Q1 		$17.8K Sell
23,145
-6,628
-22% -$6.18K ﹤0.01% 4801
2024
Q4 		$38K Buy
29,773
+2,608
+10% +$3.46K ﹤0.01% 4815
2024
Q3 		$56.2K Buy
27,165
+12,564
+86% +$58.2K ﹤0.01% 4719
2024
Q2 		$55.6K Sell
14,601
-5,786
-28% -$23.5K ﹤0.01% 4166
2024
Q1 		$96.6K Sell
20,387
-10,139
-33% -$39.4K ﹤0.01% 4448
2023
Q4 		$130K Buy
30,526
+17,210
+129% +$52.4K ﹤0.01% 4563
2023
Q3 		$41.1K Buy
13,316
+7,264
+120% +$27.3K ﹤0.01% 3949
2023
Q2 		$27.2K Sell
6,052
-4,270
-41% -$25.5K ﹤0.01% 4069
2023
Q1 		$58.8K Sell
10,322
-80,502
-89% -$491K ﹤0.01% 4392
2022
Q4 		$549K Buy
90,824
+85,656
+1,657% +$549K ﹤0.01% 3254
2022
Q3 		$34K Buy
5,168
+1,108
+27% +$7.47K ﹤0.01% 3898
2022
Q2 		$21K Sell
4,060
-1,817
-31% -$9.25K ﹤0.01% 4381
2022
Q1 		$40K Buy
+5,877
New +$53.8K ﹤0.01% 4202

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Barclays's PRLD Position: Q1 2026 in Review

Barclays reduced its Prelude Therapeutics (PRLD) stake by 0.02% in Q1 2026, selling an estimated $5 and leaving 8,600 shares worth $29.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4488.

Barclays first reported a position in PRLD in Q1 2022 and has held it in 17 quarters since. The position peaked at $549K in Q4 2022. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Barclays held 8,600 shares of Prelude Therapeutics worth $29.4K as of Q1 2026.
  • Barclays sold 2 Prelude Therapeutics shares in Q1 2026, an estimated $5.
  • Prelude Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4488 holding.
  • Barclays first reported a position in Prelude Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Prelude Therapeutics position peaked at $549K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.